Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/133"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1637"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:content	"Renal: There is limited information on the pharmacokinetics of bupropion in patients with renal impairment. An inter-study comparison between normal subjects and patients with end-stage renal failure demonstrated that the parent drug Cmax and AUC values were comparable in the 2 groups, whereas the hydroxybupropion and threohydrobupropion metabolites had a 2.3- and 2.8-fold increase, respectively, in AUC for patients with end-stage renal failure. The elimination of the major metabolites of bupropion may be reduced by impaired renal function (see PRECAUTIONS: Renal Impairment)."
dc:creator	"boycer"
dc:date	"05/14/2009 16:38:11"
rdfs:seeAlso	?:c2126e2d-3b46-40dd-8168-6d0368e5d233

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ threohydrobupropion_primary_total_clearance_mechanism_Renal_Excretion, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1637 }

Context graph